RT Journal Article
SR Electronic
T1 Chinese Stroke Association guidelines for clinical management of cerebrovascular disorders: executive summary and 2019 update of the management of high-risk population
JF Stroke and Vascular Neurology
JO Stroke Vasc Neurol
FD BMJ Publishing Group Ltd
SP 270
OP 278
DO 10.1136/svn-2020-000385
VO 5
IS 3
A1 Yilong Wang
A1 Shangrong Han
A1 Haiqiang Qin
A1 Huaguang Zheng
A1 Bin Jiang
A1 Yong Cao
A1 Yuan Gao
A1 Ling Guan
A1 Qian Jia
A1 Yong Jiang
A1 Yuming Jiao
A1 Shuya Li
A1 Yapeng Li
A1 Zixiao Li
A1 Wei Liu
A1 Xiaojuan Ru
A1 Dongling Sun
A1 Haixin Sun
A1 Penglian Wang
A1 Tingting Wang
A1 Lixia Zong
A1 Lei Guo
A1 Xuewei Xie
A1 Yuming Xu
A1 Yuyuan Xu
A1 Xiaomeng Yang
A1 Yingying Yang
A1 Mengyuan Zhou
A1 Wenzhi Wang
A1 ,
YR 2020
UL http://svn.bmj.com/content/5/3/270.abstract
AB Aim Cerebrovascular disease is the leading cause of death and disability in China, causing a huge burden among patients and their families. Hence, stroke prevention is critical, especially in the high-risk population. Here, we present the evidence-based guideline suitable for the Chinese population.Methods Literature search of PubMed and Cochrane library (from January 1964 to June 2019) was done. After thorough discussion among the writing group members, recommendations were listed and summarised. This guideline was reviewed and discussed by the fellow writing committees of the Chinese Stroke Association’s Stroke.Results This evidence-based guideline was written in three parts: controlling the risk factors of stroke, utilisation of antiplatelet agents and assessing the risks of first-ever stroke. All recommendations were listed along with the recommending classes and levels of evidence.Conclusions This guideline provides recommendations for primary prevention of cerebrovascular disease among high-risk population in China. Controlling related risk factors, appropriately using antiplatelet agents, assessing the risk of developing first-ever stroke should help reduce the rate of cerebrovascular disease in China.